McClellan’s Economic Background Could Influence FDA OTC Switch Policies
This article was originally published in The Tan Sheet
Executive Summary
Incoming FDA Commissioner Mark McClellan, MD/PhD, could have a "a high level of interest" in the issue of whether insurance firms may petition the agency to switch a drug OTC, according to CDER Office of Drug Evaluation V Director Jonca Bull, MD
You may also be interested in...
FDA, Rx Antihistamine Makers' Next Move: Compromise?
A negotiated compromise between FDA and the manufacturers of second-generation antihistamines seems the most logical way to resolve the legal, regulatory and financial obstacles facing both sides.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands